Physician profile
Edgard Pedraza
NPI 1881881324
$15,850.86
in general payments reported to CMS, 2019-2025
25 companies · $2,006 in 2025
The $2,006 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,839 · 2020: $433 · 2021: $2,971 · 2022: $2,443 · 2023: $2,914 · 2024: $2,244 · 2025: $2,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,149 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,149.35 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,687.97 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,734.82 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Abbvie INC. | $1,708.11 | 2021-2025 | |
| Alkermes, INC. | $1,690.54 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,496.88 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,436.64 | 2019-2025 | Ingrezza |
| Validus Pharmaceuticals LLC | $832.40 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $800.55 | 2019-2025 | Invega Sustenna, Spravato, Invega |
| Sunovion Pharmaceuticals INC. | $711.05 | 2019-2022 | |
| Allergan, INC. | $570.71 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $535.68 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $312.41 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $228.11 | 2023-2024 | Auvelity |
| Indivior INC. | $200.01 | 2023-2024 | Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $187.44 | 2021-2025 | Trintellix |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $170.32 | 2019-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $143.72 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $129.29 | 2021 | |
| Supernus Pharmaceuticals, INC. | $90.04 | 2022 | |
| Corium, LLC | $60.05 | 2022-2023 | Azstarys |
| Ironshore Pharmaceuticals INC. | $54.18 | 2019-2020 | |
| Shire North American Group INC | $30.75 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.25 | 2021 | |
| Neos Therapeutics, LP | $12.79 | 2019 | |
| Almatica Pharma LLC | $12.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgard Pedraza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.